Carboxyifosfamide (BioDeep_00000011265)
Secondary id: BioDeep_00001878023
human metabolite Endogenous blood metabolite
代谢物信息卡片
化学式: C7H15Cl2N2O4P (292.014646)
中文名称:
谱图信息:
最多检出来源 Homo sapiens(blood) 0.66%
分子结构信息
SMILES: C(COP(=O)(NCCCl)NCCCl)C(=O)O
InChI: InChI=1S/C7H15Cl2N2O4P/c8-2-4-10-16(14,11-5-3-9)15-6-1-7(12)13/h1-6H2,(H,12,13)(H2,10,11,14)
描述信息
Carboxyifosfamide is a metabolite of ifosfamide. Ifosfamide (also marketed as Mitoxana and Ifex) is a nitrogen mustard alkylating agent used in the treatment of cancer. It is sometimes abbreviated IFO. (Wikipedia)
D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D009588 - Nitrogen Mustard Compounds
D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D010752 - Phosphoramide Mustards
同义名列表
数据库引用编号
10 个数据库交叉引用编号
- ChEBI: CHEBI:80564
- KEGG: C16557
- PubChem: 124143
- HMDB: HMDB0060692
- Metlin: METLIN71239
- ChEMBL: CHEMBL161296
- CAS: 53459-52-2
- PMhub: MS000025237
- PubChem: 51090886
- NIKKAJI: J458.782K
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
2 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(2)
- Ifosfamide Action Pathway:
Ifosfamide + Oxygen + Water ⟶ 2-Dechloroethylifosfamide + 3-Dechloroethylifosfamide + Chloroacetaldehyde + Hydrogen peroxide - Ifosfamide Metabolism Pathway:
Ifosfamide + Oxygen + Water ⟶ 2-Dechloroethylifosfamide + 3-Dechloroethylifosfamide + Chloroacetaldehyde + Hydrogen peroxide
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- J M Singer, J M Hartley, C Brennan, P W Nicholson, R L Souhami. The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study.
British journal of cancer.
1998 Mar; 77(6):978-84. doi:
10.1038/bjc.1998.161. [PMID: 9528844] - C Joqueviel, V Gilard, R Martino, M Malet-Martino, U Niemeyer. Urinary stability of carboxycyclophosphamide and carboxyifosfamide, two major metabolites of the anticancer drugs cyclophosphamide and ifosfamide.
Cancer chemotherapy and pharmacology.
1997; 40(5):391-9. doi:
10.1007/s002800050676. [PMID: 9272115] - J M Hartley, L Hansen, S J Harland, P W Nicholson, F Pasini, R L Souhami. Metabolism of ifosfamide during a 3 day infusion.
British journal of cancer.
1994 May; 69(5):931-6. doi:
10.1038/bjc.1994.180. [PMID: 8180026] - M J Lind, H L Roberts, N Thatcher, J R Idle. The effect of route of administration and fractionation of dose on the metabolism of ifosfamide.
Cancer chemotherapy and pharmacology.
1990; 26(2):105-11. doi:
10.1007/bf02897254. [PMID: 2347037] - K Misiura, A Okruszek, K Pankiewicz, W J Stec, Z Czownicki, B Utracka. Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine.
Journal of medicinal chemistry.
1983 May; 26(5):674-9. doi:
10.1021/jm00359a010. [PMID: 6842506]